Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shandong Boan Biotechnology Company., Limited. Class H ( (HK:6955) ) has provided an update.
Shandong Boan Biotechnology Co., Ltd. reported an 8.4% increase in revenue for the first half of 2025, reaching approximately RMB393.4 million, driven by a 15.9% growth in product sales. Despite stable gross profit, the company faced increased selling and distribution expenses, while research and development expenses decreased significantly, reflecting strategic shifts in operational focus.
More about Shandong Boan Biotechnology Company., Limited. Class H
Shandong Boan Biotechnology Co., Ltd. is a joint stock company incorporated in the People’s Republic of China. It operates in the biotechnology industry, focusing on the development and sales of pharmaceutical products such as Boyounuo®, Boyoubei®, and Boluojia®.
Average Trading Volume: 24,575,190
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.17B
See more insights into 6955 stock on TipRanks’ Stock Analysis page.